Tandem Diabetes Care Inc (TNDM) - Net Assets
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has net assets worth $155.17 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($881.11 Million) and total liabilities ($725.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tandem Diabetes Care Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $155.17 Million |
| % of Total Assets | 17.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | -64.17% |
| 10-Year Change | N/A |
| Growth Volatility | 52.55 |
Tandem Diabetes Care Inc - Net Assets Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's net assets have evolved over time, based on quarterly financial data. Also explore Tandem Diabetes Care Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual net assets of Tandem Diabetes Care Inc from 2011 to 2025. For live valuation and market cap data, see TNDM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $155.17 Million | -41.02% |
| 2024-12-31 | $263.10 Million | -16.11% |
| 2023-12-31 | $313.63 Million | -28.71% |
| 2022-12-31 | $439.95 Million | +1.58% |
| 2021-12-31 | $433.11 Million | +18.24% |
| 2020-12-31 | $366.31 Million | +87.87% |
| 2019-12-31 | $194.98 Million | +48.53% |
| 2018-12-31 | $131.28 Million | +550.37% |
| 2017-12-31 | $-29.15 Million | -391.78% |
| 2016-12-31 | $-5.93 Million | -109.34% |
| 2015-12-31 | $63.47 Million | +16.30% |
| 2014-12-31 | $54.57 Million | -52.77% |
| 2013-12-31 | $115.54 Million | +208.94% |
| 2012-12-31 | $-106.05 Million | -48.75% |
| 2011-12-31 | $-71.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tandem Diabetes Care Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 117980540300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.00K | 0.04% |
| Other Comprehensive Income | $5.59 Million | 3.60% |
| Other Components | $1.40 Billion | 903.55% |
| Total Equity | $155.17 Million | 100.00% |
Tandem Diabetes Care Inc Competitors by Market Cap
The table below lists competitors of Tandem Diabetes Care Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chengdu Fusen Noble-House Industrial Co Ltd
SHE:002818
|
$1.33 Billion |
|
Gs Retail
KO:007070
|
$1.33 Billion |
|
PDF Solutions Inc
NASDAQ:PDFS
|
$1.33 Billion |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
$1.33 Billion |
|
Centuria Industrial REIT
AU:CIP
|
$1.33 Billion |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
$1.33 Billion |
|
Ecovyst Inc
NYSE:ECVT
|
$1.33 Billion |
|
Winmark Corporation
NASDAQ:WINA
|
$1.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tandem Diabetes Care Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 263,098,000 to 155,170,000, a change of -107,928,000 (-41.0%).
- Net loss of 204,710,000 reduced equity.
- Other comprehensive income increased equity by 7,540,000.
- Other factors increased equity by 89,242,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-204.71 Million | -131.93% |
| Other Comprehensive Income | $7.54 Million | +4.86% |
| Other Changes | $89.24 Million | +57.51% |
| Total Change | $- | -41.02% |
Book Value vs Market Value Analysis
This analysis compares Tandem Diabetes Care Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-4193.80 | $19.42 | x |
| 2012-12-31 | $-5641.06 | $19.42 | x |
| 2013-12-31 | $50.37 | $19.42 | x |
| 2014-12-31 | $23.45 | $19.42 | x |
| 2015-12-31 | $21.95 | $19.42 | x |
| 2016-12-31 | $-1.94 | $19.42 | x |
| 2017-12-31 | $-5.13 | $19.42 | x |
| 2018-12-31 | $2.73 | $19.42 | x |
| 2019-12-31 | $3.33 | $19.42 | x |
| 2020-12-31 | $6.01 | $19.42 | x |
| 2021-12-31 | $6.73 | $19.42 | x |
| 2022-12-31 | $6.86 | $19.42 | x |
| 2023-12-31 | $4.83 | $19.42 | x |
| 2024-12-31 | $4.02 | $19.42 | x |
| 2025-12-31 | $2.31 | $19.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tandem Diabetes Care Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -131.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.17%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 5.68x
- Recent ROE (-131.93%) is below the historical average (-45.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.38 Million |
| 2012 | 0.00% | -1334.11% | 0.06x | 0.00x | $-22.41 Million |
| 2013 | -54.65% | -217.67% | 0.18x | 1.40x | $-74.69 Million |
| 2014 | -145.72% | -159.94% | 0.47x | 1.95x | $-84.98 Million |
| 2015 | -114.10% | -99.41% | 0.58x | 1.97x | $-78.76 Million |
| 2016 | 0.00% | -99.05% | 0.75x | 0.00x | $-82.85 Million |
| 2017 | 0.00% | -67.87% | 1.13x | 0.00x | $-70.12 Million |
| 2018 | -93.40% | -66.68% | 0.89x | 1.57x | $-135.74 Million |
| 2019 | -12.70% | -6.83% | 1.11x | 1.67x | $-44.25 Million |
| 2020 | -9.39% | -6.89% | 0.70x | 1.96x | $-71.01 Million |
| 2021 | 3.59% | 2.21% | 0.78x | 2.09x | $-27.75 Million |
| 2022 | -21.50% | -11.81% | 0.76x | 2.39x | $-138.59 Million |
| 2023 | -70.98% | -29.77% | 0.78x | 3.04x | $-253.97 Million |
| 2024 | -36.50% | -10.21% | 0.97x | 3.68x | $-122.33 Million |
| 2025 | -131.93% | -20.17% | 1.15x | 5.68x | $-220.23 Million |
Industry Comparison
This section compares Tandem Diabetes Care Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,555,245,291
- Average return on equity (ROE) among peers: -57.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tandem Diabetes Care Inc (TNDM) | $155.17 Million | 0.00% | 4.68x | $1.33 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $15.99 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.10 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $125.55 Million |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more